GenSight Biologics Initiates Dose-Ranging Study for LHON Gene Therapy

Event summary

  • GenSight Biologics and The 15-20 National Hospital treated the first patient in the REVISE dose-ranging study for GS010/LUMEVOQ®, targeting ND4-LHON.
  • The open-label, single-center study aims to enroll 14 patients in France.
  • The 15-20 National Hospital is the only European institution authorized for both the REVISE study and named patient early access (AAC) treatments with GS010.
  • The REVISE study was requested by the French medicines agency ANSM during the review of the AAC program application, authorized in December 2025.

The big picture

GenSight Biologics' initiation of the REVISE study marks a critical step in advancing its gene therapy for LHON, a rare mitochondrial disease with significant unmet medical needs. The dual pathways of the REVISE study and the AAC program underscore the urgency and strategic importance of bringing this therapy to patients. The company's focus on rare retinal diseases positions it within a growing niche of gene therapy developers targeting inherited vision disorders.

What we're watching

Regulatory Dynamics
Whether the ANSM's approval process for the AAC program will set a precedent for other European countries.
Clinical Execution
The pace at which GenSight Biologics can enroll patients in the REVISE study and initiate a new Phase III clinical study by the end of 2026.
Market Expansion
How the potential opening of the AAC program to patients outside France will impact GenSight Biologics' international strategy.